To diagnose the GHD, the healthcare providers check for
conditions such as normal variations of growth, such as short familial stature;
other disorders, such as thyroid hormone deficiency or kidney disease, and
genetic conditions, can be identified using blood tests, X-ray, CT Scan, and
MRI.
Treatment is mainly done with daily injections of synthetic growth hormone, and the results are often seen just after 3-4 months of starting the treatment regimen.
The treatment can last several years until late puberty when growing is finished. GHD affects males and females equally, except for GHD III (Idiopathic GHD) which affects only males.
However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. The organization also quoted that about 73% of patients with idiopathic GHD in the National Cooperative Growth Study were males.
Additionally, patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male. “Growth Hormone Research Society perspective on biomarkers of GH action in children and adults,” which stated that in paediatric patients,
There is currently an unmet need for better predictors of GH treatment efficacy in relation to linear growth response, metabolic benefit and safety.
There is also a need for biomarkers that reflect therapeutic response in specific tissues such as the growth plate and skeleton in a variety of disorders associated with short stature.
Read More @ Pediatric Growth Hormone Deficiency Market Report
Comments
Post a Comment